Harvard Drug Continues Expansion With Watson’s Rugby OTC Business
This article was originally published in The Tan Sheet
Executive Summary
Watson Pharmaceuticals sells OTC business Rugby Laboratories to Harvard Drug Group, which operates Major Pharmaceuticals manufacturing. Watson divests a business that accounted for a small part of the private label OTC market, but keeps its pending ANDAs for guaifenesin expectorants and its smoking-cessation generics.
You may also be interested in...
Industry Roundup: Cardinal Buys Harvard Drug, Similac Lawsuit, State AGs Question Supplement Oversight
Cardinal acquires Harvard Drug; Similac ‘organic’ claims deceptive – complaint; N.Y., Ind. criticize supplement regulatory flexibility; Amway headquarters manufacturing site opens; and more news in brief.
Industry Roundup: Cardinal Buys Harvard Drug, Similac Lawsuit, State AGs Question Supplement Oversight
Cardinal acquires Harvard Drug; Similac ‘organic’ claims deceptive – complaint; N.Y., Ind. criticize supplement regulatory flexibility; Amway headquarters manufacturing site opens; and more news in brief.
In Brief
Lawmakers push energy drink investigation; Innophos buys Triarco; BASF sweetens Pronova bid; meclizine mix-up spurs iron supplement recall; Abbott Nutrition margin growth on track; Neptune’s struggles continue; Vitamin Shoppe reaches Canada; more news In Brief.